CA3192433A1 - Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia - Google Patents

Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Info

Publication number
CA3192433A1
CA3192433A1 CA3192433A CA3192433A CA3192433A1 CA 3192433 A1 CA3192433 A1 CA 3192433A1 CA 3192433 A CA3192433 A CA 3192433A CA 3192433 A CA3192433 A CA 3192433A CA 3192433 A1 CA3192433 A1 CA 3192433A1
Authority
CA
Canada
Prior art keywords
compound
hht
subject
treatment
telangiectasia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3192433A
Other languages
English (en)
French (fr)
Inventor
Damien PICARD
Pierre Saint-Mezard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaderis Therapeutics AG
Original Assignee
Vaderis Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaderis Therapeutics AG filed Critical Vaderis Therapeutics AG
Publication of CA3192433A1 publication Critical patent/CA3192433A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3192433A 2020-09-30 2021-09-29 Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia Pending CA3192433A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2015536.2 2020-09-30
GB2015536.2A GB2600384A (en) 2020-09-30 2020-09-30 Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
PCT/EP2021/076811 WO2022069552A1 (en) 2020-09-30 2021-09-29 Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Publications (1)

Publication Number Publication Date
CA3192433A1 true CA3192433A1 (en) 2022-04-07

Family

ID=73197201

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3192433A Pending CA3192433A1 (en) 2020-09-30 2021-09-29 Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Country Status (13)

Country Link
US (1) US12466839B2 (https=)
EP (1) EP4221713A1 (https=)
JP (1) JP2023543993A (https=)
KR (1) KR20230080448A (https=)
CN (1) CN116419924A (https=)
AU (1) AU2021352108B2 (https=)
BR (1) BR112023004885A2 (https=)
CA (1) CA3192433A1 (https=)
CL (1) CL2023000926A1 (https=)
GB (1) GB2600384A (https=)
IL (1) IL301466A (https=)
MX (1) MX2023002996A (https=)
WO (1) WO2022069552A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
WO2026038045A1 (en) 2024-08-15 2026-02-19 Almac Discovery Limited Crystalline forms of 6-(4-((1s,3s)-1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1h-pyrido[2,3-b][1,4]oxazin-2(3h)-one salts and free base

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI301760B (en) 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
US7910561B2 (en) 2004-12-15 2011-03-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1898903B8 (en) 2005-06-10 2013-05-15 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2008011032A1 (en) 2006-07-17 2008-01-24 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
JP2010512312A (ja) 2006-12-06 2010-04-22 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
JP2011522048A (ja) 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
US8536193B2 (en) 2008-06-03 2013-09-17 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EP2116237A1 (en) 2008-08-05 2009-11-11 Polichem SA Compositions for treating rosacea comprising chitosan and a dicarboxylic acid
EA201101186A1 (ru) 2009-02-13 2012-04-30 Байер Фарма Акциенгезельшафт Конденсированные пиримидины
GB0922589D0 (en) 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
HUE026323T2 (en) 2011-04-07 2016-05-30 Bayer Ip Gmbh Imidazopyridazines as akt kinase inhibitors
EP3294314A4 (en) 2015-05-15 2019-01-16 Memorial Sloan Kettering Cancer Center USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES
MX2020002611A (es) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Activador especifico de akt3 y usos del mismo.
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Also Published As

Publication number Publication date
US20240092801A1 (en) 2024-03-21
AU2021352108A1 (en) 2023-05-11
CN116419924A (zh) 2023-07-11
GB2600384A (en) 2022-05-04
WO2022069552A1 (en) 2022-04-07
CL2023000926A1 (es) 2023-11-03
EP4221713A1 (en) 2023-08-09
JP2023543993A (ja) 2023-10-19
MX2023002996A (es) 2023-05-03
KR20230080448A (ko) 2023-06-07
GB202015536D0 (en) 2020-11-11
AU2021352108B2 (en) 2026-04-02
US12466839B2 (en) 2025-11-11
BR112023004885A2 (pt) 2023-04-18
IL301466A (en) 2023-05-01
AU2021352108A9 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
KR102212923B1 (ko) 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
JP5808793B2 (ja) キナーゼ調節のための化合物および方法、ならびにそれらの適応症
KR102638253B1 (ko) C5a 억제제로서의 6-5 융합 고리
EP2315767B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
AU2021257373B2 (en) Pyridopyrimidinone derivatives and their use as Aryl hydrocarbon receptor modulators
WO2018177403A1 (zh) 1H-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
TWI810220B (zh) 經取代之巨環吲哚衍生物
JP2015529224A (ja) キナーゼをモジュレートするための化合物および方法、ならびにその指標
WO2012085815A1 (en) Bi-heteroaryl compounds as vps34 inhibitors
EA028035B1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
AU2021352108B2 (en) Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
CA3174507A1 (en) Imidazotriazines acting on cancer via inhibition of cdk12
AU2024290864A1 (en) Nitrogen-containing heterocyclic derivative inhibitor, and preparation method therefor and use thereof
WO2017157992A1 (en) Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
EA049324B1 (ru) Аллостерические ингибиторы akt для применения в лечении наследственной геморрагической телеангиэктазии
WO2021004482A1 (zh) 取代的吡唑并喹唑啉酮化合物及其应用
RU2780338C2 (ru) 6-5 КОНДЕНСИРОВАННЫЕ КОЛЬЦА КАК ИНГИБИТОРЫ С5а
CA3235910A1 (en) Ccr6 receptor modulators
HK1213877B (en) Compounds and methods for kinase modulation, and indications therefor

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240806

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240806

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250805

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250805

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250813

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250813

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250819

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251215

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251215

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251215

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251215

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251215

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251217